Best Medical Treatments for Parkinson s disease

Similar documents
Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University

Optimizing Clinical Communication in Parkinson s Disease:

Medications used to treat Parkinson s disease

Medication Management & Strategies When the levodopa honeymoon is over

Treatment of Parkinson s Disease: Present and Future

Parkinson s Disease Medications: Professionals Edition

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE

PD: Key Treatment Considerations

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology

parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to

Communicating About OFF Episodes With Your Doctor

Objectives. Emerging Treatments in Parkinson s s Disease. Pathology. As Parkinson s progresses it eventually affects large portions of the brain.

10th Medicine Review Course st July Prakash Kumar

Evaluation and Management of Parkinson s Disease in the Older Patient

Parkinson s Disease Current Treatment Options

The symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following:

PARKINSON S MEDICATION

Key Concepts and Issues in Parkinson s Disease in 2016

Drugs for Parkinson s Disease

Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.

Advanced Therapies for Motor Symptoms in PD. Matthew Boyce MD

What s new for diagnosing and treating Parkinson s Disease?

Parkinson s disease. Information for patients and carers. The Leeds Teaching Hospitals NHS Trust

Faculty. Joseph Friedman, MD

Parkinson s Disease. Medications

Parkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s

What is Parkinson s Disease?

Treatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS

PD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N.

Parkinson s Disease Update. Colleen Peach, RN, MSN, FNP Movement Disorders Clinic Emory University School of Medicine March 7, 2015

Parkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder

Dr Barry Snow. Neurologist Auckland District Health Board

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

Parkinsons Disease update. Sindhu R Srivatsal MD MPH Virginia Mason Medical Center

9/26/18. Objectives. Disclosures. Parkinson s Disease Update Clinical and Operational Considerations

Parkinson s Disease Update

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits

Parkinson s Disease. Gillian Sare

History Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

Drugs used in Parkinsonism

Anticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product

Welcome and Introductions

Parkinson s Disease in 60 minutes. Dr. Claire Hinnell Movement Disorder Neurologist Director Movement Disorder Clinic JPOCSC

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Literature Scan: Anti-Parkinson s Agents

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York

The Shaking Palsy of 1817

Welcome and Introductions

The Role of Pharmacists in Treating & Managing Parkinson s Disease Author: Mary Jo Carden, RPh, JD Principal, Carden Associates

Non-Motor Symptoms of Parkinson s Disease

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai

WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019

Prior Authorization with Quantity Limit Program Summary

Cardinal Features of Parkinson s. Management of Parkinson s Disease. Drug Induced Parkinson s. Other Parkinson s Symptoms.

Overview of Parkinson s disease Research at University of Colorado

Advances in Parkinson s Disease Treatment. Ryan J. Uitti, M.D. Professor of Neurology Mayo Clinic, Jacksonville, FL

PDL Class: Parkinson s Drugs

PL CE LIVE July 2015 Forum

8/28/2017. Behind the Scenes of Parkinson s Disease

475 GERIATRIC PSYCHOPHARMACOLOGY (p.1)

Drug Management of Parkinsonism. By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.)

Parkinson's Disease and how you can make a difference with medication

Depression & Anxiety. What can I do? What are other possible treatments? What is this? Why does this happen? KEY POINTS

ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM

TRANSPARENCY COMMITTEE OPINION. 18 March 2009

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August

The Fresco Institute for Parkinson's and Movement Disorders

Drugs Affecting the Central Nervous System

ARE YOUR LEVODOPA PILLS WORKING LIKE THEY USED TO?

Understanding Parkinson s Disease Important information for you and your loved ones

PARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada

Huntington s & Parkinson s Diseases: Neurologic & Psychiatric Issues. Burton Scott PhD, MD Duke Movement Disorders Center Durham, NC

Huntington s & Parkinson s Diseases: Neurologic & Psychiatric Issues. Huntington s Disease

Parkinson Disease Treatment Research Pipeline Codrin Lungu MD Program Director, Office of Clinical Research Staff Clinician, Office of the Clinical

Issues for Patient Discussion

MEDICATION GUIDE DUOPA (Do-oh-pa) (carbidopa and levodopa) enteral suspension

Appendix 2: Admissions checklists for people with Parkinson s

Summary of Patient < 3y at Visit 11 (90 months)

Parkinson s Disease and Treatment Options for the Younger Adult

PARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease

Parkinson s Disease and Treatment Options for the Younger Adult

Welcome and Introductions

Surgical Management of Parkinson s Disease

Parkinson's Disease Center and Movement Disorders Clinic

What is the best medical therapy for early Parkinson's disease? Medications Commonly Used for Parkinson's Disease

Recent Advances in the cause and treatment of Parkinson disease. Anthony Schapira Head of Dept. Clinical Neurosciences UCL Institute of Neurology UCL

Parkinson s Disease. Graham A. Glass, MD. Assistant Professor of Neurology University of California San Francisco

THE ART OF MEDICATION MANAGEMENT IN PARKINSON S DISEASE

2-The age at onset of PD is variable, usually between 50 and 80 years, with a mean onset of 55 years (1).

Introductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs

Moving fast or moving slow: an overview of Movement Disorders

Commonly encountered medications and their side effects - what the generalist needs to know

Parkinson s Pharmacology

Parkinson's Disease KP Update

OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA

CE on SUNDAY Newark, NJ October 18, 2009

Scottish Medicines Consortium

Transcription:

Best Medical Treatments for Parkinson s disease Bernadette Schöneburg, M.D. June 20 th, 2015

What is Parkinson s Disease (PD)? Progressive neurologic disorder that results from the loss of specific cells in your brain that produce a chemical called dopamine Loss of dopamine leaves patients less able to control their movement Slow Stiff Shaky

How is PD Treated? Since most symptoms of PD are caused by the lack of dopamine, many PD drugs are aimed at either temporarily replenishing or mimicking the effects of dopamine Debate over how and when to start Depends on age of the patient, severity of PD and the presence of other co-morbidities Most important factor:» The need to maintain quality of life/ability to carry out activities of daily living

Treatment does not = Medication Supportive therapies Exercise Physical therapy Occupational Therapy Speech Therapy Pharmacotherapy (medications)

How Do PD Medications Work? Dopaminergics Levodopa Dopamine Agonists MAOB Inhibitors COMT Inhibitors Others Amantadine Trihexiphenidyl

Levodopa The most efficacious drug therapy at all stages of PD Combined with carbidopa to slow its breakdown before it reaches the brain, therefore reducing side effects and increasing its availability In the US, known as sinemet Exists in immediate release and controlled release preparations

Side effects of L-dopa Short term: nausea, sleepiness, lightheadedness, confusion, hallucinations Long term: motor fluctuations and dyskinesia

Treatment of Motor Fluctuations Fluctuations can be reduced by maximizing On time Increase frequency of levodopa administration Dopamine agonists Extend the half life of levodopa by slowing the breakdown of dopamine» MAOB inhibitors» COMT inhibitors (entacapone, tolcopone)

Dopamine Agonists Pramipexole (Mirapex), Ropinirole (Requip), Rotigotine (Neupro), Apomorphine Mimic the effect of dopamine in the brain Available in immediate and controlled release formulations Can be used alone or in combination with levodopa Less effective than levodopa

Dopamine Agonists Side effects: Nausea, lightheadedness, leg swelling, hallucinations Daytime sleepiness & sleep attacks (~ 5%) Impulse control disorders (~10-15%)» Compulsive gambling, shopping, eating or hypersexuality

L-dopa vs DA DA Pros Less motor fluctuation and dyskinesia No dietary restrictions Levodopa Pros More effective Cheaper Fewer side effects ICD Leg swelling Sleep attacks Long term disability and quality of life are similar whether started on initial levodopa or dopamine agonist

MAOB-Inhibitors Selegiline (Eldepryl, Zelapar), Rasagiline (Azilect) Inhibit an enzyme that breaks down Levodopa, thus extending its action Used alone or in combination with Levodopa Mild symptomatic motor improvement

MAOB-Inhibitors Side effects: Restlessness, agitation, insomnia Drug and food interactions» Serotonin Syndrome Antidepressants Cold Medication Foods high in tyramine» Cheeses, smoked meats, fermented sausages, wine

Amantadine Most useful in early stages Tremor, fatigue, bradykinesia In later stages Reduction of dyskinesia Side effects: Decrease concentration, agitation, hallucinations, dry mouth, blurred vision Chronic use: livedo reticularis, leg swelling

Trihexyphenidyl (Artane) Most useful for Anticholinergics» Tremor in early stages» Dystonic (cramping) symptoms» Younger onset Side effects: Dry mouth, blurred vision, drowsiness, confusion, agitation

New Treatments for PD Rytary Carbidopa/levodopa ER FDA approved in January 2015 Contains IR & ER beads Designed to provide longer lasting benefit for patients When compared to standard c/l Less frequent medication dosing (3.6 vs 5 doses per day); however more total pills/day The daily total off time improved over an hour each day Caution with long term effects (dyskinesia)

Duopa Continuous intestinal carbdiopa/levodopa infusion Available in Europe since 2004 FDA approved in January 2015 for patients with advanced stage PD When compared to standard medical therapy Total daily off time improved by 2 hours Draw backs Need for small feeding Complications related to the tube or the pump are common Pump requires changing dopamine cassette once or twice per day Not been compared against DBS

Common Misperceptions I heard/read that levodopa stops working after 5 years» No I heard that levodopa is bad for you or speeds up progression» Levodopa therapy is not toxic & does not accelerate Parkinson s disease progression» In some patients, it may be the preferred drug» All therapies should be considered

Conclusion Each patient experiences a different range of symptoms Not all treatments are of equal value to all patients Work closely with your treatment team to find a regimen that is right for you